A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)
Status
Conditions
Treatments
Details and patient eligibility
About
DOL-ART is a multi-center, prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. The primary study objective is a descriptive characterization of the frequency of therapeutic monitoring measures in HIV-infected patients under dolutegravir-containing ART in routine daily practice in Germany.
The study is designed to enroll approximately 400 patients. There are no protocol-mandated visits or procedures associated with the study. Each patient is expected to participate for a maximum of 3 years or until premature discontinuation (i.e., discontinuation of dolutegravir, due to death, withdrawal of consent, lost to follow-up).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Documented HIV infection
- Age ≥ 18 years
- Decision for the first initiation of dolutegravir as part of an ART by the attending physician irrespective of inclusion in this observational study
- Prior to the start of this study, the patient must have been receiving a dolutegravir-containing ART for at least 4 weeks
Exclusion criteria
- Discontinuation of dolutegravir as part of an ART prior to the start of the study documentation
- Participation in a clinical trial during this study
- Participation in a clinical trial or compassionate use program with dolutegravir being or having been part of the investigational medication
Trial design
411 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal